Amgen Inc. headed off worse damage from Friday's news of the "black box" label warning for the firm's flagship red-blood cell boosters Aranesp and Epogen by pointing out that problems arise mainly in cases where the drugs are given at levels beyond those approved, and such cases rarely occur. (BioWorld Today)